World-renowned Specialist in advanced MRI-Guided Imaging and Treatment, Founder of multiple medical institutions
Dr. Dan Sperling is a leader in the detection of tumors through the use of image-guided technology. Dr. Sperling developed the 3T Multi-Parametric MRI – BlueLaser™ solutions. He specializes in Magnetic Resonance Imaging (MRI) which he uses for tumor detection, targeted biopsies (MRI-Guided Biopsy; tumor mapping; and treatment).
Dr. Sperling currently serves as Medical Director and Chief of Interventional Uroradiology at the Sperling Diagnostic Center and the Sperling Prostate Center. Dr. Sperling is certified by the American Board of Radiology and licensed in Massachusetts, Florida, Maryland, New York, California and New Jersey. He is also certified by the Society of Uroradiology, American Society of Laser Medicine and is an American Board of Radiology Diplomate. He completed a fellowship in oncologic PET/CT and interventional body imaging at the Albert Einstein College of Medicine at Montefiore Medical Center in New York. He completed a second fellowship in nuclear radiology at the New York University School of Medicine at Northshore University Hospital.
Dr. Sperling is a leader in diagnostic imaging, and is conversant with groundbreaking imaging technologies. As a pioneer with the largest international experience in image-guided Focal Laser Ablation (FLA) of prostate tumors, he is an expert speaker about prostate cancer detection and treatment. As a faculty member at NYU Medical Center’s annual conference for Advances in Prostate Imaging and Focal Ablative Treatment of Prostate Cancer, he presents his groundbreaking work to urologists and radiologists. He collaborates with international radiological authorities. His patient services included access to his network of specialists in other areas.
Dr. Sperling uses state-of-the-art scanning technologies to produce high definition 3D images. Dr. Sperling has helped thousands of patients and doctors improve cancer detection, treatment planning, and monitoring of results whether the intervention of choice is focal tumor ablation, surgery, radiation, surveillance or chemotherapy.